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Introduction {#jcsm12279-sec-0005}
============

Radical cystectomy (RC) with bilateral pelvic lymph node dissection is the gold‐standard treatment for muscle invasive urothelial carcinoma of the bladder (UCB) and for high‐risk non‐muscle invasive UCB resistant to intravesical therapy.[1](#jcsm12279-bib-0001){ref-type="ref"}, [2](#jcsm12279-bib-0002){ref-type="ref"} Despite curative intent, RC only provides 5 year overall survival (OS) rates of approximately 60%.[1](#jcsm12279-bib-0001){ref-type="ref"}, [2](#jcsm12279-bib-0002){ref-type="ref"} Besides histopathological characteristics, comorbidity has also been shown to affect patient outcome after RC.[3](#jcsm12279-bib-0003){ref-type="ref"}, [4](#jcsm12279-bib-0004){ref-type="ref"}

Frailty is defined as a clinical syndrome suggesting decreased physiological reserve.[5](#jcsm12279-bib-0005){ref-type="ref"} Sarcopenia is the paucity of muscle mass, which is a key component of frailty.[6](#jcsm12279-bib-0006){ref-type="ref"} Muscle mass decrease is directly responsible for functional impairment with loss of strength, increased likelihood of falling, and loss of autonomy.[7](#jcsm12279-bib-0007){ref-type="ref"}

Sarcopenia has already been investigated in different tumour entities. So far, sarcopenia was identified as a poor prognostic factor in patients undergoing surgical treatment for tumours of the respiratory tract, gastrointestinal tract, malignant melanoma, UCB, and upper urinary tract urothelial carcinoma.[8](#jcsm12279-bib-0008){ref-type="ref"}, [9](#jcsm12279-bib-0009){ref-type="ref"}, [10](#jcsm12279-bib-0010){ref-type="ref"}, [11](#jcsm12279-bib-0011){ref-type="ref"}, [12](#jcsm12279-bib-0012){ref-type="ref"}, [13](#jcsm12279-bib-0013){ref-type="ref"} Furthermore, sarcopenia has been shown to be an independent prognostic factor of survival after RC for UCB, and it was strongly associated with early complications following RC.[11](#jcsm12279-bib-0011){ref-type="ref"}, [13](#jcsm12279-bib-0013){ref-type="ref"}, [14](#jcsm12279-bib-0014){ref-type="ref"} However, only single‐centre studies with limited patient numbers or inadequate sarcopenia classifications are available.[11](#jcsm12279-bib-0011){ref-type="ref"}, [13](#jcsm12279-bib-0013){ref-type="ref"}

The aim of our study was to assess the prevalence of adequately assessed sarcopenia in a large multicentre study and to investigate its association with OS and cancer‐specific survival (CSS) in patients undergoing RC for UCB.

Patients and methods {#jcsm12279-sec-0006}
====================

Patients {#jcsm12279-sec-0007}
--------

After Institutional Review Board approval and obtaining ethics approval, 860 patients who underwent RC for UCB at three tertiary institutions between 2004 and 2014 were retrospectively identified. In 709 patients, computed tomography (CT) of the abdomen was performed as pre‐operative staging, 142 were not available as digital file, 33 were not performed within 90 days prior to RC, and 32 patients had to be excluded because of poor image quality. Of 860 patients, seven patients had neoadjuvant chemotherapy (NAC) prior to RC, of whom four patients did not have a CT after completion of NAC. Three patients had a CT after NAC, but only two were available as digital file. Because of the small number, inhomogeneity of this subgroup and risk of confounding, patients who underwent NAC were excluded. The final study cohort consisted of a total of 500 patients.

All tumours were histologically confirmed as UCB. Tumour staging was performed according to the seventh edition of the American Joint Committee on Cancer/Union Internationale Contre le Cancer TNM classification.[15](#jcsm12279-bib-0015){ref-type="ref"}

Follow‐up regimens were conducted according to institutional protocols. The cause of death was determined by chart review. A patient with metastatic disease at the time of death was categorized as having died of disease.

Pre‐operative computed tomography‐based muscle measurement {#jcsm12279-sec-0008}
----------------------------------------------------------

Sarcopenia was determined by a surrogate marker: the cross‐sectional skeletal muscle surface (cm^2^) at the level of the third lumbar vertebra (L3) on two consecutive transversal CT images on which both vertebral spines were visible.[16](#jcsm12279-bib-0016){ref-type="ref"} Computed tomography images were contrast enhanced or unenhanced 3‐ to 5‐mm‐thick multiplanar reconstructions on the axial plane. Of note, the partial volume effect can be neglected because of the almost cylindrical expansion of the musculature. Measurements were performed using Osirix™ version 7.0 (32 bit; <http://www.osirix-viewer.com>). The 'Grow Region (2D/3D Segmentation)' tool was used to automatically select all skeletal muscle mass in one transversal CT image. The distinction between different tissues is based on Hounsfield units. A threshold range of −30 to +110 Hounsfield units was used for skeletal muscle.[16](#jcsm12279-bib-0016){ref-type="ref"} Muscles measured were the psoas, paraspinal, transverse abdominal, external oblique, internal oblique, and rectus abdominis muscles (*Figure* [1](#jcsm12279-fig-0001){ref-type="fig"}A and [1](#jcsm12279-fig-0001){ref-type="fig"}B). Manual adjustment of the selected areas was performed if necessary. The averages of the two measurements were used for calculations.

![(A and B) Axial computed tomography images at the third lumbar vertebra region with skeletal muscle highlighted in orange. (A~1~--A~3~) depict variation in skeletal muscle index (SMI) for male patients with identical body mass indices (BMIs) (24.7 kg/m^2^) and different SMIs. (B~1~--B~3~) depict variation in BMI for sarcopenic female patients (SMI of 40.7 cm^2^/m^2^) and different BMIs. The orange regions represent the skeletal muscle, identified by attenuation limits of −29 to 110 Hounsfield units. The SMI is calculated by dividing the cross‐sectional area of skeletal muscle (cm^2^) by the patient\'s height squared (m^2^).](JCSM-9-505-g001){#jcsm12279-fig-0001}

Sarcopenia {#jcsm12279-sec-0009}
----------

Muscle area (cm^2^) was normalized for height in metres squared (m^2^) and reported as lumbar skeletal muscle index (SMI) (cm^2^/m^2^) According to Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"}, sarcopenia was defined as SMI of \<43 cm^2^/m^2^ for men with body mass index (BMI) \<25 kg/m^2^, SMI \<53 cm^2^/m^2^ for men with BMI ≥25 kg/m^2^, and SMI \<41 cm^2^/m^2^ for women.

Comorbidity assessment {#jcsm12279-sec-0010}
----------------------

Comorbidity was assessed based on the information from patients\' files according to the Adult Comorbidity Evaluation 27 (ACE‐27), which is a validated 27‐item comorbidity instrument for patients undergoing RC for UCB.[3](#jcsm12279-bib-0003){ref-type="ref"}, [17](#jcsm12279-bib-0017){ref-type="ref"}

Statistical analysis {#jcsm12279-sec-0011}
--------------------

Frequencies are presented as absolute numbers and percentages. Continuous data are presented as median with interquartile range (IQR). Differences between groups were analysed using the Pearson\'s *χ* ^2^ test for dichotomous parameters and the Wilcoxon--Mann--Whitney *U* test for continuous data. Survival analysis was performed with Kaplan--Meier and Cox regression analyses. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by univariable and multivariable Cox regression analyses. For the calculation of significant predictors of survival, univariable analyses with clinically relevant parameters were performed. Significant predictors (*P* \< 0.05) based on univariable analyses were included into a multivariable Cox regression analysis. *P‐*values \<0.05 were considered significant. To assess the validity of the Cox models, the proportional hazards assumption of each predictor variable was verified by using the Grambsch--Therneau residual‐based test.[18](#jcsm12279-bib-0018){ref-type="ref"} The type of relationship between SMI and OS was tested by restricted cubic splines with 5 knots at percentiles 5%, 27.5%, 50%, 72.5% and 95% as suggested by Frank Harrell in a multivariable Cox regression model.[19](#jcsm12279-bib-0019){ref-type="ref"} Optimal stratification, a statistical method similar to receiver operator curve analysis, was used to solve specific threshold values for SMI. Optimal stratification is based on log‐rank statistics that best separate patients with respect to time to death.[20](#jcsm12279-bib-0020){ref-type="ref"} Skeletal muscle index thresholds were already published by Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"}, but these values were solved in a cohort of 1.473 patients with a diagnosis of gastrointestinal or respiratory tract cancer, of whom 50% had metastatic disease. In our study, we defined threshold values related to OS for SMI, and thresholds for SMI were examined by sex and BMI and compared with the existing cut‐offs. Cox regression analyses were carried out with the threshold values published by Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"} Statistical analyses were conducted with SAS (version 9.4; SAS Institute, Cary, NC, USA) and R 3.2.2 for Windows (R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org/>).

Results {#jcsm12279-sec-0012}
=======

The median SMI among women in the study cohort was 42.3 cm^2^/m^2^ (IQR, 38.1--48.1 cm^2^/m^2^), whereas the median SMI in men was 52.2 cm^2^/m^2^ (IQR, 46.8--58.1 cm^2^/m^2^). The overall prevalence of sarcopenia in the study population was 37.8% (189/500 patients), including 43.4% of women (43/99) and 36.2% of men (145/401). Sarcopenic patients were significantly older (median pre‐operative age of 73 vs. 70 years; *P* = 0.002) but were otherwise similar regarding to comorbidity (ACE‐27), TNM stage, urinary diversion, lymphovascular invasion (LVI), carcinoma *in situ*, days between CT and surgery, administration of adjuvant chemotherapy, and soft tissue surgical margins (*P* \> 0.05 for all, *Table* [1](#jcsm12279-tbl-0001){ref-type="table-wrap"}). In addition, median BMI was significantly lower in sarcopenic patients compared with their counterparts (26.0 vs. 27.0 kg/m^2^; *P* \< 0.001). Patient characteristics are depicted in *Table* [1](#jcsm12279-tbl-0001){ref-type="table-wrap"}.

###### 

Patient characteristics of sarcopenic and non‐sarcopenic patients

  Variables                                      Entire cohort (*n* = 500)   Sarcopenic patients (*n* = 189)   Non‐sarcopenic patients (*n* = 311)    *P*‐value
  ---------------------------------------------- --------------------------- --------------------------------- ------------------------------------- -----------
  Median age at RC (IQR)                         72 (65.00--78.00)           73 (66--79)                       70 (63--77)                              0.002
  Male, *n* (%)                                  401 (80.2)                  146 (77.25)                       255 (82.0)                               0.197
  Days between CT and RC, median (IQR)           18 (8--33)                  16 (6--33)                        20 (10--33)                              0.110
  Median BMI (kg/m^2^) (IQR)                     26.3 (23.7--29.4)           26.0 (23.2--27.9)                 27.0 (23.8--30.5)                       \<0.001
  Underweight (\<20.00)                          26 (5.2)                    17 (9.0)                          9 (2.9)                                 \<0.001
  Normal weight (20.00--24.99)                   160 (32.0)                  51 (27.0)                         109 (35.0)                            
  Overweight (25.00--29.99)                      207 (41.4)                  103 (54.5)                        104 (33.4)                            
  Obese (\>29.99)                                107 (21.4)                  18 (9.5)                          89 (28.6)                             
  ACE‐27, *n* (%); missing *n* = 3                                                                                                                   
  ACE‐27: 0 (no comorbidity)                     104 (20.9)                  39 (20.6)                         65 (21.1)                                0.737
  ACE‐27: 1 (mild comorbidity)                   154 (31.0)                  64 (33.9)                         90 (29.2)                             
  ACE‐27: 2 (moderate comorbidity)               143 (28.8)                  51 (27.0)                         92 (29.9)                             
  ACE‐27: 3 (severe comorbidity)                 96 (19.3)                   35 (18.5)                         61 (19.8)                             
  Urinary diversion, *n* (%)                                                                                                                         
  Ileal conduit                                  249 (49.8)                  85 (45.0)                         164 (52.7)                               0.236
  Colon conduit                                  52 (10.4)                   21 (11.1)                         31 (10.0)                             
  Ileal neobladder                               131 (26.2)                  50 (26.5)                         81 (26.0)                             
  Sigmoid neobladder                             19 (3.8)                    10 (5.3)                          9 (2.9)                               
  Pouch                                          15 (3.0)                    5 (2.6)                           10 (3.2)                              
  Ureterocutaneostomy                            34 (6.8)                    18 (9.5)                          16 (5.1)                              
  Pathological tumour stage, *n* (%)                                                                                                                 
  pTa                                            3 (0.6)                     1 (0.6)                           2 (0.6)                                  0.753
  pTis                                           28 (5.6)                    9 (4.8)                           19 (6.1)                              
  pT1                                            66 (13.2)                   29 (15.3)                         37 (11.9)                             
  pT2                                            179 (35.8)                  63 (33.3)                         116 (37.3)                            
  pT3                                            161 (32.2)                  65 (34.4)                         96 (30.9)                             
  pT4                                            63 (12.6)                   22 (11.6)                         41 (13.2)                             
  Pathological nodal classification, *n* (%)                                                                                                         
  pN0                                            368 (73.6)                  140 (74.1)                        228 (73.3)                               0.985
  pN1                                            45 (9.0)                    16 (8.5)                          29 (9.3)                              
  pN2                                            67 (13.4)                   25 (13.2)                         42 (13.5)                             
  pN3                                            4 (0.8)                     2 (1.1)                           2 (0.6)                               
  pNx                                            16 (3.2)                    6 (3.2)                           10 (3.2)                              
  Presence of carcinoma *in situ*, *n* (%)       171 (34.2)                  61 (32.3)                         110 (35.4)                               0.479
  Presence of lymphovascular invasion, *n* (%)   200 (40.0)                  73 (38.6)                         127 (40.8)                               0.624
  Soft tissue surgical margin                                                                                                                        
  R0                                             453 (90.6)                  168 (88.9)                        285 (91.6)                            
  R1                                             41 (8.2)                    18 (9.5)                          23 (7.4)                                 0.569
  R2                                             6 (1.2)                     3 (1.6)                           3 (1.0)                               
  Adjuvant chemotherapy, *n* (%)                 65 (13.0)                   21 (11.1)                         44 (14.1)                                0.328

RC, radical cystectomy; IQR, interquartile range; BMI, body mass index; ACE‐27, Adult Comorbidity Evaluation 27; CT, computed tomography.

Calculated threshold values for SMI associated with lower survival in the current cohort are listed in *Table* [2](#jcsm12279-tbl-0002){ref-type="table-wrap"}. Spline curves of adjusted HR for OS show a linear correlation between 48 and 55 cm^2^/m^2^, while in the lower and upper quartiles, a change of SMI shows no further effect on OS (*Figure* [2](#jcsm12279-fig-0002){ref-type="fig"}). The calculated threshold values from the current cohort differed only to a little extent to the published threshold values from Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"} (*Table* [2](#jcsm12279-tbl-0002){ref-type="table-wrap"}).

###### 

Skeletal muscle index threshold values significantly associated with low overall survival in the current study cohort and the cohort of Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"}

  BMI (kg/m^2^)    Current study cohort   Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"}       
  --------------- ---------------------- --------------------------------------------------------- ---- ----
  \<25                      48                                      40                              43   41
  ≥25                       52                                      43                              53   41

![Restricted cubic spline with 5 knots at percentiles 5%, 27.5%, 50%, 72.5%, and 95% (vertical dotted lines) showing the relationship between skeletal muscle index (SMI) (cm^2^/m^2^) and hazard ratios of overall survival (red line). Ninety‐five per cent confidence interval is indicated by the dotted blue lines. The model is adjusted for significant covariates depicted in *Table* [3](#jcsm12279-tbl-0003){ref-type="table-wrap"}.](JCSM-9-505-g002){#jcsm12279-fig-0002}

The median follow‐up for survivors was 35 months (IQR, 20--58 months). The median overall follow‐up of patients was 22 months (IQR, 10--45 months). Two hundred thirty‐four (46.8%) patients died, with 145 (29%) of these dying because of UCB. In addition, patients with sarcopenia had a significantly decreased 5 year OS (38.3% vs. 50.5%, *P* = 0.002, *Figure* [3](#jcsm12279-fig-0003){ref-type="fig"}A) and CSS (49.5% vs. 62.3%, *P* = 0.016, *Figure* [3](#jcsm12279-fig-0003){ref-type="fig"}B) compared with non‐sarcopenic patients.

![(A and B) Kaplan--Meier plots depicting overall survival and cancer‐specific survival in sarcopenic and non‐sarcopenic patients undergoing radical cystectomy for urothelial carcinoma of the bladder.](JCSM-9-505-g003){#jcsm12279-fig-0003}

In univariable analysis, age, sarcopenia, higher ACE‐27, higher pathological tumour (pT) stage, lymph node metastasis, LVI, positive surgical margins, and adjuvant chemotherapy were significantly associated with decreased OS and CSS after RC for UCB (*Tables* [3](#jcsm12279-tbl-0003){ref-type="table-wrap"} and [4](#jcsm12279-tbl-0004){ref-type="table-wrap"}). In the multivariable Cox regression analysis, age, comorbidity (ACE‐27), pathological tumour and nodal stage, LVI, surgical margin rates, and administration of adjuvant chemotherapy as additional covariates, the presence of sarcopenia remained significantly associated with increased all‐cause mortality after RC (HR, 1.43; 95% CI 1.09--1.87; *P* = 0.01). This model provides a c‐index of 0.754. The same multivariable model with the SMI cut‐offs derived from our cohort provides a c‐index of 0.760. In addition, sarcopenia was also significantly associated with increased cancer‐specific mortality (HR, 1.42; 95% CI, 1.00--2.02; *P* = 0.048) after adjusting for age, ACE‐27, pathological tumour and nodal stage, LVI surgical margin rates after RC, and administration of adjuvant chemotherapy (*Table* [4](#jcsm12279-tbl-0004){ref-type="table-wrap"}). The multivariable model regarding CSS provides a c‐index of 0.802, and the multivariable model with our SMI cut‐offs provides a c‐index of 0.801. No violations of the proportional hazards assumption and the linearity assumption were found.

###### 

Univariate and multivariable Cox regression models addressing prediction of overall survival after radical cystectomy for urothelial carcinoma of the bladder

  Variables                                                    Univariate analysis   Multivariable analysis                                 
  ------------------------------------------------------------ --------------------- ------------------------ --------- ------ ------------ ---------
  Age at RC (continous)                                        1.043                 1.03--1.06               \<0.001    1.03   1.01--1.04  0.002
  Gender (reference: male)                                     1.28                  0.94--1.74               0.123      ---       ---      ---
  Presence of sarcopenia (reference: absence)                  1.50                  1.16--1.94               0.002      1.43   1.09--1.87  0.01
  pT stage                                                                                                                                  
  pT2 (reference: ≤pT1)                                        1.12                  0.71--1.78               0.633      0.98   0.61--1.58  0.94
  pT3 (reference: ≤pT1)                                        3.36                  2.19--5.14               \<0.001    1.95   1.22--3.14  0.006
  pT4 (reference: ≤pT1)                                        4.46                  2.78--7.17               \<0.001    2.11   1.20--3.70  0.009
  Presence of CIS (reference: absence)                         0.78                  0.59--1.02               0.071      ---       ---      ---
  Presence of LVI (reference: absence)                         2.86                  2.20--3.72               \<0.001    1.72   1.25--2.38  0.001
  Positive soft tissue surgical margin (reference: negative)   4.39                  3.14--6.147              \<0.001    2.41   1.63--3.55  \<0.001
  pN stage                                                                                                                                  
  pN+ (reference: pN0)                                         3.15                  2.39--4.14               \<0.001    1.73   1.24--2.41  0.001
  pNx (reference: pN0)                                         2.90                  1.60--5.24               \<0.001    1.81   0.98--3.34  0.056
  ACE‐27                                                                                                                                    
  ACE‐27: 1 (reference: ACE‐27 0)                              1.22                  0.81--1.84               0.333      1.14   0.76--1.70  0.526
  ACE‐27: 2 (reference: ACE‐27 0)                              1.60                  1.08--2.37               0.019      1.56   1.04--2.34  0.033
  ACE‐27: 3 (reference: ACE‐27 0)                              1.60                  1.08--2.37               0.004      1.75   1.12--2.73  0.013
  Adjuvant chemotherapy (reference: not administered)          1.64                  1.17--2.28               0.004      0.83   0.55--1.23  0.347
  Body mass index                                                                                                                           
  Underweight (reference: normal weight)                       0.80                  0.59--1.08               0.140      ---       ---      ---
  Overweight (reference: normal weight)                        0.81                  0.57--1.16               0.258      ---       ---      ---
  Obese (reference: normal weight)                             1.15                  0.65--2.03               0.625      ---       ---      ---

CI, confidence interval; RC, radical cystectomy; CIS, carcinoma *in situ*; LVI, lymphovascular invasion; ACE‐27, Adult Comorbidity Evaluation 27.

###### 

Univariate and multivariable Cox regression models addressing the prediction of cancer‐specific survival after radical cystectomy for urothelial carcinoma of the bladder

  Variables                                                     Univariate analysis  Multivariable analysis                                  
  ------------------------------------------------------------ --------------------- ------------------------ --------- ------ ------------- ---------
  Age at RC (continous)                                                1.03          1.01--1.05               0.002      1.01   0.99--1.033  0.206
  Gender (reference: male)                                             1.32          0.89--1.96               0.163      ---        ---      ---
  Presence of sarcopenia (reference: absence)                          1.49          1.07--2.07               0.018      1.42   1.00--2.02   0.048
  pT stage                                                                                                                                   
  pT2 (reference: ≤pT1)                                                1.64          0.80--3.35               0.184      1.33   0.64--2.77   0.442
  pT3 (reference: ≤pT1)                                                6.71          3.46--13.02              \<0.001    3.54   1.73--7.24   0.001
  pT4 (reference: ≤pT1)                                                8.57          4.20--17.46              \<0.001    3.20   1.41--7.27   0.005
  Presence of CIS (reference: absence)                                 0.78          0.55--1.11               0.164      ---        ---      ---
  Presence of LVI (reference: absence)                                 3.72          2.65--5.22               \<0.001    1.81   1.20--2.73   0.005
  Positive soft tissue surgical margin (reference: negative)           5.89          3.92--8.83               \<0.001    3.24   2.01--5.23   \<0.001
  pN stage                                                                                                                                   
  pN+ (reference: pN0)                                                 4.14          2.95--5.81               \<0.001    1.79   1.19--2.70   0.005
  pNx (reference: pN0)                                                 2.57          1.12--5.91               0.026      1.75   0.74--4.15   0.202
  ACE‐27                                                                                                                                     
  ACE‐27: 1 (reference: ACE‐27 0)                                      1.15          0.70--1.89               0.588      1.13   0.68--1.89   0.639
  ACE‐27: 2 (reference: ACE‐27 0)                                      1.34          0.82--2.20               0.249      1.49   0.90--2.50   0.130
  ACE‐27: 3 (reference: ACE‐27 0)                                      1.74          1.04--2.92               0.036      1.81   1.03--3.17   0.039
  Adjuvant chemotherapy (reference: not administered)                  2.72          1.87--3.94               \<0.001    1.11   0.70--1.75   0.67
  Body mass index                                                                                                                            
  Underweight (reference: normal weight)                               0.85          0.59--1.24               0.394      ---        ---      ---
  Overweight (reference: normal weight)                                0.75          0.47--1.19               0.221      ---        ---      ---
  Obese (reference: normal weight)                                     0.79          0.34--1.84               0.587      ---        ---      ---

CI, confidence interval; RC, radical cystectomy; CIS, carcinoma *in situ*; LVI, lymphovascular invasion; ACE‐27, Adult Comorbidity Evaluation 27; BMI, body mass index.

Discussion {#jcsm12279-sec-0013}
==========

The aim of the present study was to assess the frequency of sarcopenia and determine its impact on survival in a large multicentre cohort of patients undergoing RC for UCB. We defined sarcopenia by sex‐specific and BMI‐specific threshold values according to the Martin criteria, which were determined from 1473 cancer patients using optimal stratification of lower survival and therefore represents the most accurate CT‐derived sarcopenia classification.[8](#jcsm12279-bib-0008){ref-type="ref"}

Thirty‐seven per cent of the patients in our cohort were classified as sarcopenic. In a recently published Japanese single‐centre study of 136 patients undergoing RC for UCB, 65 patients (47.8%) were classified as sarcopenic.[13](#jcsm12279-bib-0013){ref-type="ref"} Although in both cohorts sarcopenia has been classified according to the Martin criteria, differences in sarcopenia frequencies might be explained because of the retrospective and non‐consecutive fashion of the cohorts. In contrast, Psutka *et al*.[11](#jcsm12279-bib-0011){ref-type="ref"} reported a study of 205 patients, of whom 141 patients (68.8%) were sarcopenic according to the criteria defined by Fearon *et al*.[6](#jcsm12279-bib-0006){ref-type="ref"} The applied classification by Psutka *et al*.[11](#jcsm12279-bib-0011){ref-type="ref"} has two important drawbacks: first, the used CT‐based threshold values were converted from dual energy X‐ray absorptiometry based threshold values, which were defined as values two standard deviations below the sex‐specific means in young healthy adults. This conversion was based on only 31 patients, who underwent both dual energy X‐ray absorptiometry and CT.[21](#jcsm12279-bib-0021){ref-type="ref"}, [22](#jcsm12279-bib-0022){ref-type="ref"} Second, the threshold values were not BMI specific. The threshold values reported from Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"} (*Table* [2](#jcsm12279-tbl-0002){ref-type="table-wrap"}) were calculated from a large patient cohort with a diagnosis of gastrointestinal and respiratory tract cancer, of whom 50% had metastatic disease. To investigate whether these established SMI threshold values are suitable for non‐metastatic bladder cancer patients, SMI threshold values from our cohort were calculated, which differed only to a little extent compared with the established values from Martin *et al*.[8](#jcsm12279-bib-0008){ref-type="ref"} (*Table* [2](#jcsm12279-tbl-0002){ref-type="table-wrap"}). In addition, the predictive capacity for OS and CSS showed only a minimal improvement and confirms the applicability in bladder cancer patients.

The most important finding in the current study is the independent association of sarcopenia and increased cancer‐specific mortality (HR, 1.42; 95% CI, 1.00--2.02; *P* = 0.048) and increased all‐cause mortality (HR, 1.43; 95% CI 1.09--1.87; *P* = 0.01). These results are in concordance with the previous published literature. Psutka *et al*.[11](#jcsm12279-bib-0011){ref-type="ref"} were able to demonstrate that sarcopenia was an independent predictor of CSS (HR 2.14; 95% CI 1.24--3.71; *P* = 0.007) and OS (HR 1.93; 95% CI 1.23--3.00; *P* = 0.004). Hirasawa *et al*.[13](#jcsm12279-bib-0013){ref-type="ref"} demonstrated that sarcopenia was an independent predictor of CSS in a single‐centre cohort of 136 patients (HR 2.3; 95% CI 1.2--4.4; *P* = 0.015). However, this study was limited by a small sample size and a small number of events (*n* = 42), and therefore, an overfitting bias in the multivariate analysis must be taken into account. In contrast, a study reported by Smith *et al*.[10](#jcsm12279-bib-0010){ref-type="ref"} including 200 patients undergoing RC for UCB could not demonstrate an association between survival and sarcopenia, which was classified by the total psoas area. However, their study was limited by a median follow‐up of 16 months, and sarcopenia was assessed by total psoas area, which is lacking validated threshold values. Even in metastatic UCB, sarcopenia was shown to be an independent predictor of poor CSS (HR 2.07; 95% CI 1.01--4.67; *P* = 0.045).[23](#jcsm12279-bib-0023){ref-type="ref"}

Comorbidity indices such as the ACE‐27 score and the Charlson comorbidity index have been evaluated as predictors for survival after RC for UCB.[3](#jcsm12279-bib-0003){ref-type="ref"}, [4](#jcsm12279-bib-0004){ref-type="ref"} Our findings clearly demonstrate that sarcopenia is an important predictor of survival in UCB independent of the degree of comorbidity. Assessment of sarcopenia by calculation of SMI is quick and simple using free software and CT images without special training. Furthermore, sarcopenia is a highly objective measure because one can estimate the composition of the human body using CT with a precision error of 1.4%.[24](#jcsm12279-bib-0024){ref-type="ref"}

Sarcopenia has important implications for clinical practice, because the decline of skeletal muscle mass is potentially reversible.[25](#jcsm12279-bib-0025){ref-type="ref"} Adequate calorie and protein intake, combined with resistance training, are the key components in the management of sarcopenic patients.[26](#jcsm12279-bib-0026){ref-type="ref"}, [27](#jcsm12279-bib-0027){ref-type="ref"} A prospective Japanese single‐centre study demonstrated that sarcopenic patients older than 65 years undergoing gastrectomy for gastric cancer had significantly lower caloric and protein intake per day and had significantly more severe complications.[28](#jcsm12279-bib-0028){ref-type="ref"} Interestingly, the same research group investigated 22 sarcopenic patients undergoing gastrectomy for gastric cancer and established a pre‐operative exercise and nutritional support programme, which resulted in a significantly higher calorie and protein intake per day and increased handgrip strength.[29](#jcsm12279-bib-0029){ref-type="ref"} In addition, four of the 22 investigated patients became non‐sarcopenic after the support programme. In the previously mentioned study by Hirasawa *et al*.,[13](#jcsm12279-bib-0013){ref-type="ref"} it was demonstrated that sarcopenic patients showed significantly lower haemoglobin levels than non‐sarcopenic patients. As recently shown in a randomized controlled trial, patients with iron‐deficiency anaemia undergoing major open abdominal surgery showed significantly reduced blood transfusions and length of hospital stay, when administered perioperative intravenous iron.[30](#jcsm12279-bib-0030){ref-type="ref"} Perioperative iron transfusion could therefore complement the nutritional support programme in sarcopenic patients with iron‐deficiency anaemia. In addition, the prevention of muscle loss is a necessary precondition for autonomy for older people. Food supplements with proteins, leucine, vitamin D, and antioxidants delay progression of sarcopenia and also stimulate muscular protein synthesis.[31](#jcsm12279-bib-0031){ref-type="ref"}, [32](#jcsm12279-bib-0032){ref-type="ref"} Alternatively, anabolic hormones such as testosterone, oestrogen, and growth factors can play a role in the prevention, delay, and regression of sarcopenia.[32](#jcsm12279-bib-0032){ref-type="ref"}

To the best of our knowledge, this is the largest and first multicentre study (*n* = 500) reporting sarcopenia as a prognostic factor in patients undergoing RC, classifying sarcopenia according to the Martin criteria.[8](#jcsm12279-bib-0008){ref-type="ref"} A further strength of the current paper is that the multivariate model was adjusted for comorbidity, which is an independent predictor of survival after RC for UCB.[3](#jcsm12279-bib-0003){ref-type="ref"} In our analyses, ACE‐27 was used as quantification tool for comorbidity, as it is the most accurate comorbidity index and it has been robustly evaluated in 17 712 cancer patients.[17](#jcsm12279-bib-0017){ref-type="ref"}

Our study is not free of limitations. In this survey, we collected data from 500 patients in a non‐consecutive fashion due to its retrospective nature. In addition, the current study was limited by the finding that many of the patients who underwent RC during 2004--2014 did not have digital CT scans available for SMI analysis and therefore were excluded from the final analysis. Given its retrospective nature, we were unable to correlate SMI with other metrics of frailty such as performance status on patient questionnaires or walking speed or grip strength tests and nutritional status. To overcome this limitation, a prospective multicentre study should be performed to acquire a consecutive patient cohort with a prospective frailty assessment. However, the assessment of skeletal muscle mass was not limited because of the prospective acquisition of CT images. A further notable limitation of the study is the reduced frequency of patients undergoing NAC, which have therefore not been included in the final analysis. Even though NAC frequencies of 20% have been reported in the USA in 2010, a prospective European RC study from 2011 demonstrated frequency rates of 2%, which is in concordance with our study.[33](#jcsm12279-bib-0033){ref-type="ref"}, [34](#jcsm12279-bib-0034){ref-type="ref"} However, to investigate the impact of sarcopenia in patients undergoing NAC, further studies are needed.

Taken together, sarcopenia is an objective risk factor for prediction of CSS and OS in patients with UCB undergoing RC. The identification of patients with sarcopenia is important as their outcome may be improved by pre‐operative exercise and nutritional support programmes prior to RC.
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